Ann: Kazia progress update, page-2

Key Points
• EVT801 phase I study protocol has cleared third dose level and is recruiting well.
• GBM AGILE pivotal study has opened in France, the fourth country to commence
recruitment to the paxalisib arm.
• Phase I study of paxalisib in combination with radiotherapy for treatment of brain
metastases at Memorial Sloan Kettering Cancer Center has been accepted for
presentation at an upcoming academic conference in Q3 CY2022.
• ATM financing facility has realized gross proceeds of US$ 2,956,036 for the period
ending June 2022, at an average price of $6.08 (approximately AU$ 0.88 per share).